As the fourth leading cause of cancer death in the United States, pancreatic cancer remains one of the most deadly forms of cancer. More than 90 percent of patients die within the first year of diagnosis. Recent advancements have had little impact, and a new approach is desperately needed.
As featured in Time Magazine, Penn Medicine’s Dr. Jeffery Drebin and the Stand Up 2 Cancer Pancreatic Dream Team is answering that call. Their team-based multi-disciplinary approach is translating scientific breakthroughs into new treatment options faster than ever before.
Dr. Drebin and the pancreatic cancer dream team is focused on developing tests using advanced imaging technology to understand pancreatic cancer cells and developing new, personalized pancreatic cancer treatments based on their research.
About Pancreatic Cancer
Pancreatic cancer is cancer that develops within the pancreas, the gland about six inches long that is responsible for making hormones, including the enzymes responsible for the digestion of food and control of blood sugar.
Pancreatic cancer develops when cells within the pancreas begin to grow out of control. It may spread, or metastasize, to nearby lymph nodes and organs such as the liver and lungs.
About Pancreatic Cancer Treatment at Penn Medicine
At Penn Medicine, patients with pancreatic cancer receive their care from a multidisciplinary team of nationally recognized experts in the diagnosis, treatment and research of gastrointestinal cancer.
Penn Medicine's multidisciplinary approach to cancer diagnosis and treatment provides better outcomes and gives patients access to the most advanced treatment, surgical techniques and clinical trials.
Learn more about Pancreatic Cancer Treatment at the ACC